Logo

Pharmacia Turns to Genaissance for Pharmacogenomics

Dec 17, 2002

NEW YORK, Dec. 17-Genaissance will supply pharmacogenomics services for Pharmacia, the company said today.

 

Through this agreement, Genaissance will use its HAP technology to probe the genetics of drug response for compounds in clinical trials at Pharmacia.

 

Genaissance already has pharmacogenomic partnerships with AstraZeneca, Johnson & Johnson and Pfizer.

 

Financial details of the relationship were not disclosed, although Genaissance says that partnerships based on its HAP technology generally swap haplotype data access and services for a package that includes licensing fees, service fees, milestone payments and royalties.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.